We found no striking differences in expression of known co-inhibitory or co-stimulatory molecules such as PD-L1, CD80/86, or 4-1BB that might explain the differential tumor cell sensitivity to CD20xCD3 bsAb (Supplemental Fig. 2). The gene discussed is CD80; the disease is neoplasm.